| Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer S Yang, SPY Che, P Kurywchak, JL Tavormina, LB Gansmo, ... Cancer biology & therapy 18 (3), 158-165, 2017 | 229 | 2017 |
| Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis M Tachezy, F Gebauer, M Janot, W Uhl, A Zerbi, M Montorsi, J Perinel, ... Surgery 160 (1), 136-144, 2016 | 151 | 2016 |
| Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer F Gebauer, D Wicklein, J Horst, P Sundermann, H Maar, T Streichert, ... PloS one 9 (11), e113023, 2014 | 104 | 2014 |
| Age‐and sex‐related changes of humeral head microarchitecture: histomorphometric analysis of 60 human specimens F Barvencik, M Gebauer, FT Beil, E Vettorazzi, M Mumme, M Rupprecht, ... Journal of orthopaedic research 28 (1), 18-26, 2010 | 98 | 2010 |
| Activated leukocyte cell adhesion molecule (CD166)—its prognostic power for colorectal cancer patients M Tachezy, H Zander, F Gebauer, A Marx, JT Kaifi, JR Izbicki, M Bockhorn journal of surgical research 177 (1), e15-e20, 2012 | 89 | 2012 |
| Improved risk stratification by circulating tumor cell counts in pancreatic cancer KE Effenberger, C Schroeder, A Hanssen, S Wolter, C Eulenburg, ... Clinical Cancer Research 24 (12), 2844-2850, 2018 | 87 | 2018 |
| Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA-a … M Tachezy, F Gebauer, C Petersen, D Arnold, M Trepel, K Wegscheider, ... BMC cancer 14, 1-9, 2014 | 85 | 2014 |
| Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? F Gebauer, M Tachezy, YK Vashist, AH Marx, E Yekebas, JR Izbicki, ... World journal of surgery 39, 493-499, 2015 | 76 | 2015 |
| Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp−−/rag2−− mice F Gebauer, D Wicklein, K Stübke, N Nehmann, A Schmidt, J Salamon, ... Gut 62 (5), 741-750, 2013 | 74 | 2013 |
| Multivisceral resections in pancreatic cancer: identification of risk factors CM Burdelski, M Reeh, D Bogoevski, F Gebauer, M Tachezy, YK Vashist, ... World journal of surgery 35, 2756-2763, 2011 | 74 | 2011 |
| The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma H Loeser, M Kraemer, F Gebauer, C Bruns, W Schröder, T Zander, ... Oncoimmunology 8 (5), e1581546, 2019 | 72 | 2019 |
| High surgical morbidity following distal pancreatectomy: still an unsolved problem M Reeh, MF Nentwich, D Bogoevski, AM Koenig, F Gebauer, M Tachezy, ... World journal of surgery 35, 1110-1117, 2011 | 72 | 2011 |
| ABO Blood Group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer BT Hofmann, A Stehr, T Dohrmann, C Güngör, L Herich, J Hiller, S Harder, ... Clinical Cancer Research 20 (23), 6117-6126, 2014 | 70 | 2014 |
| Options and limitations in applying the fistula classification by the International Study Group for Pancreatic Fistula F Gebauer, K Kloth, M Tachezy, YK Vashist, G Cataldegirmen, JR Izbicki, ... Annals of surgery 256 (1), 130-138, 2012 | 69 | 2012 |
| Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer LM Schiffmann, M Fritsch, F Gebauer, SD Günther, NR Stair, JM Seeger, ... British journal of cancer 120 (1), 69-78, 2019 | 66 | 2019 |
| Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma F Gebauer, M Tachezy, K Effenberger, K von Loga, H Zander, A Marx, ... Journal of surgical oncology 104 (2), 140-145, 2011 | 66 | 2011 |
| HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma PS Plum, F Gebauer, M Krämer, H Alakus, F Berlth, SH Chon, ... BMC cancer 19, 1-9, 2019 | 64 | 2019 |
| ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients M Tachezy, K Effenberger, H Zander, S Minner, F Gebauer, YK Vashist, ... International journal of cancer 131 (2), 396-405, 2012 | 64 | 2012 |
| Activated leukocyte cell adhesion molecule (CD166): an “inert” cancer stem cell marker for non-small cell lung cancer? M Tachezy, H Zander, G Wolters-Eisfeld, J Müller, D Wicklein, F Gebauer, ... Stem Cells 32 (6), 1429-1436, 2014 | 58 | 2014 |
| ALCAM (CD166) expression and serum levels in pancreatic cancer M Tachezy, H Zander, AH Marx, PR Stahl, F Gebauer, JR Izbicki, ... PloS one 7 (6), e39018, 2012 | 49 | 2012 |
